Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes and Novartis’ $12 billion merger agreement to acquire Avidity Biosciences.
FDA Approval of Lynkuet
The FDA has approved Bayer’s Lynkuet, also known as elinzanetant, as the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
The approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
Non-Hormonal Option
As a non-hormonal option, Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
New research suggests Ozempic may reduce biological age.
Author summary: Ozempic may reduce biological age according to new research.
More News
- Cloud's new performance leader: Arm beats x86
- Importing beef is not the solution | GABEL
- What Your Urine Tests Can Reveal That Your Blood Tests Might Not - Daylifenews
- AI tool paints bigger picture of global impact of millions of research grants, papers and patents
- Elon Musk's xAI Launches Grok-powered 'Grokipedia' Encyclopedia
- Schenectady launches school zone camera demonstration program
- An NYPD Camera Points Directly Into Their Bedroom. They’re Suing the City Over It.
- How to Download and Play Battlefield 6 Battle Royale (RedSec)
- Suspect in Charlie Kirk killing can wear street clothes in court amid ‘extraordinary’ attention | Fulton Sun
- This Logitech mouse might be the most comfortable thing at my desk.